Drug Search Results
More Filters [+]

Diethylcarbamazine

Alternative Names: diethylcarbamazine, hetrazan
Latest Update: 2024-06-03
Latest Update Note: Clinical Trial Update

Product Description

Diethylcarbamazine is an Anthelmintic. Diethylcarbamazine is a N-methylpiperazine and a N-carbamoylpiperazine. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Diethylcarbamazine)

Mechanisms of Action: Arachidonic Acid Metabolism Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Brazil | Canada | France | Greece | India | Indonesia | Ireland | New Zealand | Pakistan | Philippines | Saudi Arabia | Sri Lanka | Taiwan | Thailand | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diethylcarbamazine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title